Schedule of Contract Assets and Contract Liabilities

Total contract assets at September 30, 2023 were as follows:


(In thousands)	Contract Assets
Contract assets at December 31, 2022	$	8,929
Additions		12,881
Transferred to receivables, net		(19,044	)
Contract assets at September 30, 2023	$	2,766

Total contract liabilities at September 30, 2023 were as follows:


(In thousands)	Contract Liabilities
Contract liabilities at December 31, 2022	$	10,701
Additions		(931	)
Amounts recognized into revenue		(4,794	)
Contract liabilities at September 30, 2023	$	4,976

Schedule of Disaggregation of Revenues

During the three and nine months ended September 30, 2023 and 2022, the Company recorded product sales, net, as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2023		2022		2023		2022
VIVITROL	$	99,305	$	96,534	$	298,035	$	277,493
ARISTADA and ARISTADA INITIO		81,834		75,719		244,320		222,826
LYBALVI		50,683		27,127		135,671		61,116
Total product sales, net	$	231,822	$	199,380	$	678,026	$	561,435

Schedule of Disaggregation of Revenues

During the three and nine months ended September 30, 2023 and 2022, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:


	Three Months Ended September 30, 2023						Nine Months Ended September 30, 2023
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total		Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	76,109	$	76,109	$	—	$	410,910	$	410,910
VUMERITY		9,733		24,828		34,561		32,751		62,979		95,730
RISPERDAL CONSTA		14,732		151		14,883		30,049		957		31,006
Other		16,157		7,403		23,560		48,160		22,082		70,242
	$	40,622	$	108,491	$	149,113	$	110,960	$	496,928	$	607,888


	Three Months Ended September 30, 2022								Nine Months Ended September 30, 2022
(In thousands)	Manufacturing Revenue		Royalty Revenue			Total			Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	26,737		$	26,737		$	—	$	90,439	$	90,439
VUMERITY		5,584		20,666			26,250			22,629		60,386		83,015
RISPERDAL CONSTA		8,380		1,848			10,228			32,529		5,516		38,045
Other		3,265		(13,539	)		(10,274	)		26,472		5,466		31,938
	$	17,229	$	35,712		$	52,941		$	81,630	$	161,807	$	243,437

(1)

“Long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).